Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1586/era.12.152
Reference26 articles.
1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
2. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
4. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
5. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Potential of Iron Oxide Nanoparticles as Drug Delivery Vehicle;Topics in Mining, Metallurgy and Materials Engineering;2021
2. Gold Nanoparticles- Boon in Cancer Theranostics;Current Pharmaceutical Design;2020-11-27
3. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy;Cancer Cell International;2020-09-15
4. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy;Acta Biomaterialia;2020-01
5. A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models;Oncology and Therapy;2016-09-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3